EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Quanterix's Enterprise Value is $335.5 Mil.
Quanterix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-48.2 Mil. Therefore, Quanterix's EV-to-EBIT for today is -6.97.
The historical rank and industry rank for Quanterix's EV-to-EBIT or its related term are showing as below:
QTRX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -86.72 Med: -13.54 Max: 0.03
Current: -6.91
During the past 9 years, the highest EV-to-EBIT of Quanterix was 0.03. The lowest was -86.72. And the median was -13.54.
QTRX's EV-to-EBIT is ranked worse than 100% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 19.86
vs QTRX: -6.91
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Quanterix's Enterprise Value for the quarter that ended in Dec. 2023 was $759.4 Mil.
Quanterix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-48.2 Mil. Quanterix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -6.34%.
Quanterix EV-to-EBIT Historical Data
The historical data trend for Quanterix's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Quanterix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quanterix EV-to-EBIT Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Quanterix's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Quanterix's EV-to-EBIT falls into.
Quanterix EV-to-EBIT Calculation
Quanterix's EV-to-EBIT for today is calculated as:
Quanterix's current Enterprise Value is $335.5 Mil.
Quanterix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quanterix (NAS:QTRX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Quanterix's Enterprise Value for the quarter that ended in Dec. 2023 was $759.4 Mil.
Quanterix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quanterix EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Quanterix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QTRX has been successfully added to your 